Indegene Limited
INDGN.BO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$137.34B
Close$
$910.51
51.8% upside
Current Fair Value
51.8% upsideUndervalued by 51.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $137.34 Billion |
|---|---|
| Enterprise Value | $137.34 Billion |
| Annual dividend | $2.25 |
| Dividend yield | 0.40% |
| Earnings per Share | $16.72 |
| Beta | 0.75 |
| Outstanding Shares | 240,528,646 |
Return
| Return on Equity | 12.77% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 34.01 |
|---|---|
| PEG | -19796.71 |
| Price to Sales | 3.8 |
| Price to Book Ratio | 4.61 |
| Enterprise Value to Revenue | 3.6 |
| Enterprise Value to EBIT | 25.08 |
| Enterprise Value to Net Income | 34 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$4.63
Consensus analyst estimateRevenue Estimate
$10.65 B
Consensus analyst estimateNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$4.77
Consensus analyst estimateRevenue Estimate
$11.04 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Indegene Limited
4,687 employees
CEO: Manish Gupta
Indegene Limited operates as a global commercialization partner within the life sciences sector. The company assists biopharmaceutical, nascent biotechnology, and medical device organizations throughout their product's journey, from init...